Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") highlights the potential for its DPXtm non-systemic immune educating platform to address the inherent limitations of lipid ...

In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

Researchers have developed a new microscopic method to observe the interactions of therapeutic antibodies with target molecules on tumor cells.

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and — due to innovations in manufacturing — could make future cellular ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their ...